Tags

Type your tag names separated by a space and hit enter

Effect of montelukast on peripheral airflow obstruction in children with asthma.
Ann Allergy Asthma Immunol. 2006 Apr; 96(4):541-9.AA

Abstract

BACKGROUND

Montelukast is a widely used controller agent in childhood asthma. It is modestly effective in reducing symptoms, decreasing the need for rescue albuterol, and improving forced expiratory volume in 1 second (FEV1).

OBJECTIVE

To determine whether montelukast therapy improves peripheral airway obstruction as measured by lung volumes, air trapping, airway resistance (Raw), and specific conductance (Sgaw).

METHODS

Twenty-one children aged 9 to 18 years with mild-to-moderate asthma were randomized into a double-blind, placebo-controlled study to receive montelukast (5 or 10 mg) or matching placebo daily for 8 weeks. Symptoms and albuterol use were recorded twice daily, and exhaled nitric oxide measurement, forced oscillometry, spirometry, and body box plethysmography (before and after beta-agonist use) were performed at randomization and at 2, 4, 6, and 8 weeks. Circulating eosinophil counts and serum eosinophil cationic protein (ECP) levels were obtained at randomization and at 8 weeks.

RESULTS

Montelukast-treated patients had lower residual volume (P = .05), residual volume-total lung capacity ratio (P = .04), Raw (P = .02), Sgaw (P = .03), and serum ECP levels (P = .02) at 8 weeks compared with those treated with placebo. There was a trend toward reduced daytime and nighttime albuterol use, although the difference did not reach statistical significance. There were no significant differences in FEV1, FEV1-forced vital capacity ratio, exhaled nitric oxide levels, or daytime and nighttime symptom scores between the 2 groups.

CONCLUSIONS

Montelukast therapy was associated with less air trapping, hyperinflation, and Raw and better Sgaw compared with placebo. Lower serum ECP levels, a surrogate measure of airway inflammation, were associated with improvements in lung function.

Authors+Show Affiliations

Division of Clinical Pharmacology, Department of Pediatrics, National Jewish Medical and Research Center, University of Colorado Health Sciences Center, Denver 80206, USA. spahnj@njc.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16680924

Citation

Spahn, Joseph D., et al. "Effect of Montelukast On Peripheral Airflow Obstruction in Children With Asthma." Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, vol. 96, no. 4, 2006, pp. 541-9.
Spahn JD, Covar RA, Jain N, et al. Effect of montelukast on peripheral airflow obstruction in children with asthma. Ann Allergy Asthma Immunol. 2006;96(4):541-9.
Spahn, J. D., Covar, R. A., Jain, N., Gleason, M., Shimamoto, R., Szefler, S. J., & Gelfand, E. W. (2006). Effect of montelukast on peripheral airflow obstruction in children with asthma. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 96(4), 541-9.
Spahn JD, et al. Effect of Montelukast On Peripheral Airflow Obstruction in Children With Asthma. Ann Allergy Asthma Immunol. 2006;96(4):541-9. PubMed PMID: 16680924.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of montelukast on peripheral airflow obstruction in children with asthma. AU - Spahn,Joseph D, AU - Covar,Ronina A, AU - Jain,Neal, AU - Gleason,Melanie, AU - Shimamoto,Reed, AU - Szefler,Stanley J, AU - Gelfand,Erwin W, PY - 2006/5/10/pubmed PY - 2006/7/1/medline PY - 2006/5/10/entrez SP - 541 EP - 9 JF - Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology JO - Ann Allergy Asthma Immunol VL - 96 IS - 4 N2 - BACKGROUND: Montelukast is a widely used controller agent in childhood asthma. It is modestly effective in reducing symptoms, decreasing the need for rescue albuterol, and improving forced expiratory volume in 1 second (FEV1). OBJECTIVE: To determine whether montelukast therapy improves peripheral airway obstruction as measured by lung volumes, air trapping, airway resistance (Raw), and specific conductance (Sgaw). METHODS: Twenty-one children aged 9 to 18 years with mild-to-moderate asthma were randomized into a double-blind, placebo-controlled study to receive montelukast (5 or 10 mg) or matching placebo daily for 8 weeks. Symptoms and albuterol use were recorded twice daily, and exhaled nitric oxide measurement, forced oscillometry, spirometry, and body box plethysmography (before and after beta-agonist use) were performed at randomization and at 2, 4, 6, and 8 weeks. Circulating eosinophil counts and serum eosinophil cationic protein (ECP) levels were obtained at randomization and at 8 weeks. RESULTS: Montelukast-treated patients had lower residual volume (P = .05), residual volume-total lung capacity ratio (P = .04), Raw (P = .02), Sgaw (P = .03), and serum ECP levels (P = .02) at 8 weeks compared with those treated with placebo. There was a trend toward reduced daytime and nighttime albuterol use, although the difference did not reach statistical significance. There were no significant differences in FEV1, FEV1-forced vital capacity ratio, exhaled nitric oxide levels, or daytime and nighttime symptom scores between the 2 groups. CONCLUSIONS: Montelukast therapy was associated with less air trapping, hyperinflation, and Raw and better Sgaw compared with placebo. Lower serum ECP levels, a surrogate measure of airway inflammation, were associated with improvements in lung function. SN - 1081-1206 UR - https://www.unboundmedicine.com/medline/citation/16680924/Effect_of_montelukast_on_peripheral_airflow_obstruction_in_children_with_asthma_ DB - PRIME DP - Unbound Medicine ER -